- Preview Available
- Scholarly Journal
Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China
Scientific Reports (Nature Publisher Group); London Vol. 15, Iss. 1, (2025): 10147.
DOI:10.1038/s41598-025-91540-9
This is a limited preview of the full PDF
Try and log in through your library or institution to see if they have access.